| Ethel Bibay, NP | |
|
1700 Mount Vernon Ave, Bakersfield, CA 93306-4018 | |
| (661) 326-2000 | |
| Not Available |
| Full Name | Ethel Bibay |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Pediatrics |
| Location | 1700 Mount Vernon Ave, Bakersfield, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316371370 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0200X | Clinical Nurse Specialist - Pediatrics | 22893 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ethel Bibay, NP 2201 Mount Vernon Ave, Suite 113, Bakersfield, CA 93306-3341 Ph: (661) 868-8269 | Ethel Bibay, NP 1700 Mount Vernon Ave, Bakersfield, CA 93306-4018 Ph: (661) 326-2000 |
News Archive
Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.
Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers.
Understanding how and why we evolved such large brains is one of the most puzzling issues in the study of human evolution. It is widely accepted that brain size increase is partly linked to changes in diet over the last 3 million years, and increases in meat consumption and the development of cooking have received particular attention from the scientific community.
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
Human Genome Sciences announced that BENLYSTA™ met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). These results show that BENLYSTA™ has the potential to become the first new approved drug in decades giving hope to people living with systemic lupus.
› Verified 4 days ago